Dr. Jonathan Trent discusses the FDA approval of trabectedin for patients with soft tissue sarcomas.
Jonathan Trent, MD
Advertisement
Articles by Jonathan Trent, MD
Advertisement
Latest Updated Articles
Dr. Jonathan Trent on FDA Approval of Trabectedin for Soft Tissue SarcomasPublished: November 5th 2015 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
